<DOC>
	<DOC>NCT00418379</DOC>
	<brief_summary>A phase III study to evaluate Long term efficacy , carry-over effect and safety of 300 IR sublingual Immunotherapy (SLIT) tablets in adults patients suffering from grass pollen rhinoconjunctivitis</brief_summary>
	<brief_title>Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets</brief_title>
	<detailed_description />
	<criteria>Male or female outpatients aged 18 to 50 years Grass pollenrelated allergic rhinoconjunctivitis for at least the last two pollen seasons Positive SPT and specific IgE values of at least Class 2 for grass pollen allergens A score of greater than or equal to 12 out of a possible 18 on the Retrospective Rhinoconjunctivitis Total Symptom Score (RRTSS) Patients with symptoms of rhinoconjunctivitis during the grass pollen season due to sensitisation to allergens other than grass pollen must not be included. Patients must be asymptomatic to all other allergens during the grass pollen season. Patients who have allergic rhinitis due to perennial allergen may not be included. Asthma requiring treatment other than beta2 inhaled agonists. Patients who have received any desensitisation treatment for grass pollen or with any other allergen within the previous 5 years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sublingual immunotherapy</keyword>
	<keyword>Grass pollen tablet</keyword>
	<keyword>Allergic rhinoconjunctivitis</keyword>
</DOC>